natgillin/translations-raw huggingface dataset:
Safety and tolerability of bosentan was investigated in an exploratory, uncontrolled 12-week study in 11 patients with pulmonary hypertension secondary to severe COPD (stage III of GOLD classification). 
Sigurnost i podnošljivost bosentana ispitana je u eksploratornij, nekontroliranoj 12-tjednoj studiji na
Efficacy in adult patients with pulmonary arterial hypertension Two randomised, double-blind, multi-centre, placebo-controlled studies have been conducted in 32 (study AC-052-351) and 213 (study AC-052-352 [BREATHE-1]) adult patients with WHO functional class III-IV PAH (primary pulmonary hypertension or pulmonary hypertension secondary mainly to scleroderma). 
32 (studija AC-052-351) i 213 (studija AC-052-352 [BREATHE-1]) odrasla bolesnika s PAH-om
A careful benefit/risk assessment should be made, taking into consideration the liver toxicity of bosentan (see sections 4.4 and 4.8). 
Treba napraviti pažljivu procjenu koristi i rizika, uzimajući u obzir da je bosentan toksičan za jetru
Cellulose microcrystalline Calcium hydrogen phosphate anhydrous Croscarmellose sodium Silica colloidal anhydrous Tartaric acid 
Drugi sastojci su mikrokristalična celuloza, kalcijev hidrogenfosfat, bezvodni, karmelozanatrij,
Liver aminotransferase levels must be measured prior to initiation of treatment and subsequently at monthly intervals for the duration of treatment with Tracleer. 
Prije početka liječenja i svaki mjesec tijekom liječenja Tracleerom treba izmjeriti vrijednosti jetrenih aminotransferaza.
Jun ______ 
Rujan _____
Jan ______ 
Studeni _____
• Gastrooesophageal reflux disease (acid reflux) 
• Ciroza (stvaranje ožiljaka) jetre, zatajenje jetre (teški poremećaj funkcije jetre)
In the adult placebo-controlled studies, a decrease in haemoglobin concentration to below 10 g/dL from baseline was reported in 8.0% of bosentan-treated patients and 3.9% of placebo-treated patients (see section 4.4). 
g/dl od početne vrijednosti prijavljeno je kod 8,0% bolesnika koji su dobivali bosentan i 3,9%
164 ng·h/mL, n = 11). 
U stanju dinamičke ravnoteže AUCτ je bila 6165 ng•h/mL (CV: 133%, n =
Тел. 
Vas.
Re-introduction of treatment 
Učinci liječenja
Slovak Republic Actavis Group PTC ehf Reykjavikurvegi 76-78 
Češka Republika Actavis Group PTC ehf Reykjavikurvegi 76-78
EU/2/19/239/001 Baycox Iron 
EU/2/19/239/001 Baycox Iron 36 mg/ml / 182 mg/mL
Piglets 
Karencija
Meat and offal: 53 days 
53 dana.
Intramuscular use 
Intramuskularna injekcija
Each ml contains: 
Svaki ml sadržava:
Date of first authorisation: 09/12/2015 
Datum prvog odobrenja: 09/12/2015
More than 74% of cabergoline is bound to plasma protein. 
Više od 74% kabergolina je vezano za proteine plazme.
Velactis reduces milk production. 
Velactis smanjuje lučenje mlijeka.
Meat and offal: 23 days 
Meso i jestive iznutrice: 23 dana
Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required. 
Pitajte vašeg veterinara ili ljekarnika kako odlagati lijekove koji vam više nisu potrebni.
Prolactin inhibitor 
inhibitor prolaktina
Approximately 66% of the administered dose is eliminated by faeces. 
Približno 66% primijenjene doze eliminira se fecesom.
This veterinary medicinal product does not require any special storage condition. 
Ovaj veterinarsko-medicinski proizvod ne zahtijeva nikakve posebne uvjete čuvanja.
The active substance in Velactis is cabergoline, an allowed substance as described in table 1 of the annex to Commission Regulation (EU) No 37/2010: 
Djelatna tvar u Velactisu je kabergolin, dozvoljena tvar kako je navedeno u tablici 1, Dodatka Uredbe Komisije (EU) br. 37/2010:
The veterinary medicinal product may cause skin sensitization. 
Veterinarsko-medicinski proizvod može izazvati senzibilizaciju kože.
Do not use after the expiry date which is stated on the carton after EXP. 
Ne koristiti nakon isteka roka valjanosti naznačenog na kutiji poslije EXP.
This was observed following 1.5-2 times of the recommended dose and was more pronounced at higher doses. 
To je uočeno nakon primjene doza 1,5-2 puta većih od preporučene i bilo je izraženije pri većim dozama.
(There are no data on pregnancy outcome in humans following injection of cabergoline, but studies in laboratory animals have shown a risk for embryonic death following repeat oral exposure to cabergoline.) 
(Nema podataka o ishodu trudnoće u ljudi nakon injiciranja kabergolina, ali su ispitivanja na laboratorijskim životinjama pokazala da postoji rizik od smrti embrija nakon ponovljene peroralne izloženosti kabergolinu.)
The excipients listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required, or are considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product. 
Pomoćne tvari navedene u dijelu 6.1 SPC su ili dozvoljene tvari za koje je u tablici 1, Dodatka Uredbe Komisije (EU) br. 37/2010 naznačeno da određivanje MRL nije nužno ili se smatra da se na njih ne primjenjuju odredbe Uredbe (EK) br. 470/2009 kada se primjenjuju u tim veterinarsko medicinskim proizvodima.
Urine is the second pathway of elimination. 
Sekundarni put eliminacije je urin.
Velactis should not enter water courses as this may be dangerous for fish and other aquatic organisms. 
Velactis se ne smije se odlagati u otvorene vode jer to može biti opasno za ribe i druge vodene organizme.
Detailed information on this product is available on the website of the European Medicines Agency http://www.ema.europa.eu 
Detaljne informacije o ovom veterinarsko-medicinskom proizvodu dostupne su na web stranici Europske agencije http://www.ema.europa.eu
Studies in laboratory animals have shown a risk for embryonic death following repeat oral exposure to cabergoline. 
Ispitivanja na laboratorijskim životinjama pokazala su da postoji rizik od smrti embrija nakon ponovljene peroralne izloženosti kabergolinu.
Shelf-life after first opening the immediate packaging: 28 days. 
Rok trajanja poslije prvog otvaranja unutarnjeg pakovanja: 28 dana.
Cabergoline is rapidly metabolized principally by liver, and is eliminated with a mean half-life of about 20 h. 
Kabergolin se brzo metabolizira uglavnom u jetri i eliminira se uz srednju vrijednost poluživota od otprilike 20 sati.
Pharmacotherapeutic group: Other gynaecologicals, prolactin inhibitors, cabergoline ATCvet code: QG02CB03 
Farmakoterapijska grupa: Ostali ginekološki pripravci, inhibitori prolaktina, kabergolin ATCvet kod: QG02CB03
If you notice any serious effects or any other effects not mentioned in this package leaflet, please inform your veterinary surgeon. 
Ako zamijetite bilo koju ozbiljnu nuspojavu ili druge nuspojave koje nisu opisane u uputi o VMP, molimo obavijestite svog veterinara.
Fatal meteorism has been observed in a single cow following a second administration of 5 times the recommended dose. 
Fatalni meteorizam je uočen kod jedne krave nakon druge primjene doze 5 puta veće od preporučene.
Normal aseptic procedures for administration of an intramuscular injection should be followed. 
Treba slijediti uobičajene aseptične postupke za primjenu intramuskularne injekcije.
This could theoretically decrease the metabolisation of cabergoline, and prolong its persistence in plasma from cows treated concomitantly with Velactis and such products. 
To bi teoretski moglo usporiti metabolizam kabergolina te produljiti njegovo zadržavanje u plazmi kod krava koje su istovremeno liječene Velactisom i takvim proizvodima.
In the absence of data on pregnancy outcome in humans following injection of cabergoline, pregnant women and women attempting to conceive should avoid contact with the product. 
U nedostatku podataka o ishodu trudnoće u ljudi nakon injiciranja kabergolina, trudnice i žene koje pokušavaju začeti trebaju izbjegavati doticaj s proizvodom.
Overdose (symptoms, emergency procedures, antidotes), if necessary Overdoses resulted in some cases in slight and transient decrease of appetite. 
Predoziranje (simptomi, hitni postupci, antidoti), ako je nužno Predoziranje je u nekim slučajevima uzrokovalo blago i prolazno smanjenje apetita.
MARKETING AUTHORISATION NUMBER(S) EU/2/15/192/001-004 
BROJ(EVI) ODOBRENJA ZA STAVLJANJE U PROMET EU/2/15/192/001-004
Only use a dry sterile needle and avoid the introduction of humidity/water during use. 
Koristite samo suhu sterilnu iglu kako biste izbjegli unos vlage/vode tijekom primjene.
TARGET SPECIES Cattle (dairy cows) 
CILJNE VRSTE ŽIVOTINJA Goveda (muzne krave)
Cattle (dairy cows) 
Goveda (muzne krave).
Excipients: For the full list of excipients, see section 6.1 
Pomoćne tvari: Potpuni popis pomoćnih tvari vidi u odjeljku 6.1.
Meat and offal: 23 days Milk: - Zero hours after calving when the dry period length is 32 days or more. 
Meso i jestive iznutrice: 23 dana Mlijeko: - Nula sati nakon telenja ako je suhostaj trajao 32 dana ili dulje.
Administer the veterinary medicinal product with caution to avoid self-injection. 
Veterinarsko-medicinski proizvod primjenjujte oprezno kako biste izbjegli samoinjiciranje.
The product should be injected within 4 hours after the last milking. 
Proizvod treba injicirati unutar 4 sata nakon zadnje mužnje.
SPECIAL WARNING(S), IF NECESSARY Read the package leaflet before use 
POSEBNA UPOZORENJA, UKOLIKO JE POTREBNO Pročitati uputu o VMP prije primjene
Three consecutive administrations of 1, 3 or 5 times the recommended dose may result in transient and reversible slight elevation of plasma glucose levels. 
Tri uzastopne primjene doze 1, 3 ili 5 puta veće od preporučene može dovesti do prolaznog i reverzibilnog blagog povišenja razina glukoze u plazmi.
Therefore, Velactis-treated cows should not be allowed to have access to open water, and should not contaminate watercourses with faeces until at least 5 days after administration. 
Zato krave tretirane Velactisom ne smiju imati pristup otvorenoj vodi te se vodeni tokovi ne smiju kontaminirati njihovim fecesom najmanje 5 dana nakon primjene.
Consequently, cabergoline administration induces a reduction of milk production leading to a reduction in udder engorgement and intramammary pressure. 
Posljedično, primjena karbegolina uzrokuje smanjenje proizvodnje mlijeka i dovodi do smanjenja nabreklosti vimena i intramamarnog pritiska.
The administration of three or five times the recommended dose for 3 consecutive days (i.e. corresponding to 9 and 15 times the recommended dose, respectively) resulted in addition in some cases in transient and reversible digestive signs such as diarrhoea. 
Primjena doza tri ili pet puta većih od preporučene tijekom 3 uzastopna dana (odgovara 9 odnosno 15 puta većim dozama od preporučene) u nekim je slučajevima dovelo i do prolaznih i reverzibilnih probavnih znakova kao što je proljev.
For use in the herd management programme of dairy cows as an aid in the abrupt drying-off by reducing milk production to: - reduce milk leakage at drying off, - reduce the risk of new intramammary infections during the dry period, - reduce discomfort. 
Za primjenu u planiranom upravljanju stadom muznih krava kao pomoć pri naglom zasušivanju smanjivanjem lučenja mlijeka kako bi se: - smanjilo curenje mlijeka tijekom isušivanja, - smanjio rizik novih intramamarnih infekcija tijekom suhostaja, - smanjila nelagoda.
For the 25 ml, 50 ml and the 5x5ml only: Once broached, use within 28 days. 
Samo za pakovanja od 25 ml, 50 ml i 5x5ml: Nakon otvaranja, upotrijebite unutar 28 dana.
Cabergoline is a synthetic ergot derivative, which is a potent dopamine receptor agonist on D2 receptors. 
Kabergolin je sintetski derivat ergolina koji je snažan agonist D2 dopaminskih receptora.
Overdoses resulted in some cases in slight and transient decrease of appetite. 
Predoziranje je u nekim slučajevima uzrokovalo blago i prolazno smanjenje apetita.
Brown glass vials closed by bromobutyl stoppers and crimped with aluminium and plastic flip capsules. 
Bočice od smeđeg stakla zatvorene bromobutilnim čepovima obavijenim s aluminijskom kapicomi s plastičnim "flip-off" zatvaračima.
Clear pale yellow solution. 
Bistra blijedo žuta otopina.
- 4 days (8 milkings) after calving when the dry period length is less than 32 days 
- 4 dana (8 mužnji) nakon telenja ako je suhostaj trajao kraće od 32 dana.
Subsequently udder pain and discomfort are reduced at one and two days after drying off, respectively. 
Posljedično se bol i nelagoda u vimenu smanjuju tijekom jednog odnosno dva dana nakon zasušivanja.
After intramuscular administration in cattle, the systemic absorption of cabergoline is rapid and important (bioavailability over 90%), with a peak concentration observed around 3 h after administration and followed by a high tissue distribution. 
Nakon intramuskularne primjene u goveda, sistemska apsorpcija kabergolina je brza i značajna (biodostupnost preko 90%), s vršnom koncentracijom uočenom otprilike 3 sata nakon primjene popraćenom visokim stupnjem tkivne distribucije.
The cows should be diagnosed to be free of subclinical mastitis by using suitable criteria such as bacterial examination of milk, somatic cell count or other recognized tests. 
Odsutnost subkliničkog mastitisa u krava treba potvrditi prema odgovarajućim kriterijima kao što su bakteriološki pregled mlijeka, broj somatskih stanica ili drugi priznati testovi.
The veterinary medicinal product may cause skin sensitisation and persons with a known hypersensitivity to cabergoline or any of the excipients should avoid contact with it. 
Veterinarsko-medicnski proizvod može uzrokovati senzibilizaciju kože i osobe preosjetljive na kabergolin ili bilo koju od pomoćnih tvari trebaju izbjegavati kontakt s njim.
In vitro, some macrolide antibiotics, like erythromycin, inhibited the activity of bovine Cytochrom P 450-enzymes (CYP3A4-subclass). 
In vitro su neki makrolidni antibiotici, kao eritromicin, inhibirali aktivnost goveđih enzima citokroma P450 (podvrsta CYP3A4).
Velactis should be used as part of a comprehensive mastitis and milk quality control program under veterinarian advice, which might include the need to use intramammary treatment. 
Velactis treba koristiti kao dio sveobuhvatnog programa kontrole mastitisa i kvalitete mlijeka što može uključivati i potrebu intramamarne terapije pod nadzorom veterinara.
The product should be administered within 4 hours after the last milking. 
Proizvod treba primijeniti unutar 4 sata nakon zadnje mužnje.
QUANTITY OF THE ACTIVE SUBSTANCE(S) 1.12 mg/ml 
KOLIČINA DJELATNE(IH) TVARI 1,12 mg/ml
Pregnant or breastfeeding women and women attempting to conceive should avoid contact with the solution and should be prevented from an accidental self-injection. 
Trudnice ili žene koje doje te žene koje pokušavaju začeti trebaju izbjegavati kontakt s otopinom i spriječiti slučajno samoinjiciranje.
Cardboard box with 1 vial of 5 ml, 25 ml or 50 ml, or 5 vials of 5 ml. 
Kartonska kutija s jednom bočicom od 5 ml, 25 ml ili 50 ml; ili 5 bočica od 5 ml.
Milk: - zero hours after calving when the dry period length is 32 days or more. 
Mlijeko: - nula sati nakon telenja ako je suhostaj trajao 32 dana ili dulje.
Cabergoline should not enter surface waters as it has harmful effects on aquatic species. 
Kabergolin ne smije dospjeti u površinske vode jer štetno djeluje na vodene organizme.
Persons with a known hypersensitivity to cabergoline or any of the excipients should avoid contact with the veterinary medicinal product. 
Osobe preosjetljive na kabergolin ili na bilo koju od pomoćnih tvari trebaju izbjegavati kontakt s veterinarsko-medicinskim proizvodom.
The recommended dose is 5.6 mg of cabergoline (corresponding to 5 ml of solution for injection) per animal in one single injection at the day of drying-off after the last milking. 
Preporučena doza je 5,6 mg kabergolina (odgovara 5 ml otopine za injekciju) po životinji u jednoj jednokratnoj injekciji na dan zasušivanja nakon zadnje mužnje.
The difference between groups was 13.7% (95% confidence interval 6.4-21%). 
Razlika između skupina bila je 13,7% (95% interval pouzdanosti; 6,4-21%).
It acts on dopamine receptors of prolactin producing cells in the pituitary gland suppressing the prolactin production and leading to the inhibition of prolactin secretion dependent process. 
Djeluje na dopaminske receptore stanica koje proizvode prolaktin u hipofizi suprimirajući proizvodnju prolaktina i dovodeći do inhibicije procesa ovisnih o lučenju prolaktina.
In a multicentric randomized clinical trial where dairy cows with no intramammary infections at the time of drying-off were administered either Velactis or placebo at the time of drying-off, the incidence of new intramammary infections within 7 days after subsequent calving was significantly lower among udder quarters of cows treated with Velactis (20.5%) as compared to placebo (26.0%). 
U multicentričkom randomiziranom kliničkom ispitivanju u kojem je u muznih krava bez intramamarne infekcije u vrijeme zasušivanja primjenjivan Velactis ili placebo u vrijeme zasušivanja, učestalost novih intramamarnih infekcija unutar 7 dana nakon telenja bila je značajno niža u četvrtima vimena krava liječenih Velactisom (20,5%) u usporedbi s placebom (26,0%).
In a randomized and placebo controlled clinical study, reduced discomfort was demonstrated during the first day after drying-off by increasing daily lying time by 143 +/- 17 minutes in Velactis treated animals in comparison with untreated controls. 
U randomiziranom i placebom kontroliranom kliničkom ispitivanju pokazalo se smanjenje nelagode tijekom prvog dana nakon zasušivanja koje se manifestiralo produženjem vremena ležanja za 143 +/- 17 minuta u životinja liječenih Velactisom u usporedbi s neliječenim životinjama.
DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED Detailed information on this product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/). 
Detaljne informacije o ovom veterinarsko-medicinskom proizvodu dostupne su na web stranici Europske agencije za lijekove (http://www.ema.europa.eu/).
In a randomized and placebo controlled clinical study Velactis treated cows presented less signs of udder pain in comparison with controls on the first two days after drying-off. 
U randomiziranom i placebom kontroliranom kliničkom ispitivanju krave liječene Velactisom pokazivale su manje znakova boli u vimenu u usporedbi s kontrolama u prva dva dana nakon zasušivanja.
At 9 times the recommended dose a decrease in ruminal activity may be observed. 
Pri dozama 9 puta većima od preporučene može se uočiti smanjeno preživanje.
In the same study, incidence of milk leakage was significantly lower among Velactis treated animals (2.0%) as compared to placebo treated animals (10.7%). 
U istom ispitivanju učestalost curenja mlijeka bila je značajno niža u životinja liječenih Velactisom (2,0%) u usporedbi sa životinjama liječenim placebom (10,7%).
cabergoline 
NUSPOJAVE
The recommended dose is 5.6 mg of cabergoline (corresponding to 5 ml of Velactis) per animal in one single injection at the day of drying-off after the last milking. 
Preporučena doza je 5,6 mg kabergolina (odgovara 5 ml Velactisa) po životinji u jednoj jednokratnoj injekciji na dan zasušivanja, nakon zadnje mužnje.
The difference between groups was 8.7% (95% confidence interval 4.9-12.6%). 
Razlika između skupina bila je 8,7% (95% interval pouzdanosti; 4,9-12,6%).
The product should only be used in dairy cows at the time of drying-off. 
Proizvod treba primjenjivati samo u muznih krava u vrijeme zasušivanja.
Disposal: read package leaflet 
Odlaganje: Pročitati uputu o VMP
This was confirmed in another multicentric randomized clinical trial where incidence of milk leakage was significantly lower among Velactis treated animals (3.9%) as compared to placebo treated animals (17.6%). 
To je potvrđeno u još jednom multicentričnom randomiziranom kliničkom ispitivanju u kojem je učestalost curenja mlijeka bila značajno niža u životinja liječenih Velactisom (3,9%) u usporedbi sa životinjama liječenim placebom (17,6%).
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements. 
6.6 Posebne mjere prilikom odlaganja neupotrebljenog veterinarsko-medicinskog proizvoda ili otpadnih materijala dobivenih primjenom tog proizvoda Bilo koji neupotrebljeni veterinarsko-medicinski proizvod ili otpadni materijali dobiveni primjenom tih veterinarsko-medicinskih proizvoda trebaju se odlagati u skladu s propisima o zbrinjavanju otpada.
Therefore, the product should only be administered to dairy cows at the time of drying-off. 
Zato proizvod treba primjenjivati samo u muznih krava u vrijeme zasušivanja.
The efficacy of Velactis in reducing the risk of new intramammary infections during the dry period when administered concomitantly with antimicrobial treatment to cows with intramammary infections has not been investigated compared to antimicrobial treatment alone. 
Djelotvornost primjene Velactisa zajedno s antimikrobnim liječenjem u usporedbi s primjenom samo antimikrobnog liječenja za smanjenje rizika od novih intramamarnih infekcija tijekom suhostaja kod krava s intramamarnim infekcijama nije istraživana.
In case of accidental self-injection, seek medical advice, and show this package leaflet or the label to the physician. 
U slučaju da se nehotice samoinjicira, potražite pomoć liječnika i pokažite mu ovu uputu o VMP ili etiketu.
CONTRAINDICATIONS Do not use in case of hypersensitivity to cabergoline or to any of the excipients. 
KONTRAINDIKACIJE Ne primjenjivati u slučaju preosjetljivosti na kabergolin ili na bilo koju od pomoćnih tvari.
Slight injection site reactions (mostly swellings) were commonly observed after injection of the product and may persist for at least 7 days. 
Nakon injiciranja lijeka često su zapažene blage reakcije na mjestu primjene (uglavnom oticanje) koje mogu potrajati najmanje 7 dana.
Cardboard box of 5 ml vial Cardboard box of 25 ml vial Cardboard box of 50 ml vial Cardboard box of 5x5 ml vials 
Kartonska kutija s bočicom od 5 ml Kartonska kutija s bočicom od 25 ml Kartonska kutija s bočicom od 50 ml Kartonska kutija s 5 bočica od 5 ml
The difference in percentage of new intramammary infections during the dry period between Velactis treated animals and the placebo group was 5.5% (95% confidence interval 0.5-10.4%). 
Razlika u postotku novih intramamarnih infekcija tijekom suhostaja između skupina životinja liječenih Velactisom i placebom bila je 5,5% (95% interval pouzdanosti; 0,5-10,4%).
However, administration of tylosin concomitantly with Velactis in cows did not show any changes of Velactis pharmacokinetic properties. 
Ipak, primjena tilozina zajedno s Velactisom nije pokazala nikakve promjene farmakokinetičkih svojstava Velactisa.
WITHDRAWAL PERIOD Withdrawal period: See box 
KARENCIJA Karencija: Vidjeti kutiju
Do not use in case of hypersensitivity to cabergoline or to any of the excipients. 
Ne primjenjivati u slučaju preosjetljivosti na kabergolin ili na bilo koju od pomoćnih tvari.
In case of accidental self-injection, seek medical advice, and show the package leaflet or the label to the physician. 
U slučaju da se nehotice samoinjicira, potražite pomoć liječnika i pokažite mu uputu o VMP ili etiketu.
However, administration of tylosin concomitantly with Velactis in cows did not show any changes of cabergoline pharmacokinetic properties. 
Ipak, primjena tilozina zajedno s Velactisom nije pokazala nikakve promjene farmakokinetičkih svojstava kabergolina.
Dimethyl sulfoxide Triglycerides, medium-chain 
6.1 Popis pomoćnih tvari dimetilsulfoksid srednjelančani trigliceridi
METHOD AND ROUTE(S) OF ADMINISTRATION Intramuscular use 
NAČIN I PUT(EVI) PRIMJENE Intramuskularna primjena.
The difference in occurrence of pain was 9.9% (95% confidence interval 4-15.8%) between the Velactis treated cows compared to placebo treated animals. 
Razlika u pojavi boli bila je 9,9% (95% interval pouzdanosti; 4-15,8%) između krava liječenih Velactisom i životinja liječenih placebom.
STATEMENT OF ACTIVE AND OTHER SUBSTANCES 1 ml contains 1.12 mg of cabergoline. 
I DRUGIH TVARI 1 ml sadržava 1,12 mg kabergolina.